Do IL6 rs1800795 GG and CRP rs1205 CT increase hs-CRP responsiveness?

The interleukin-6 (IL-6) to C-reactive protein (CRP) pathway is a primary cascade regulating systemic inflammation. Variations in this pathway determine how dynamically an individual's high-sensitivity CRP (hs-CRP) levels rise in response to upstream inflammatory cues.

Mechanistic pathways

• Upstream transcription: The IL6 rs1800795 promoter variant directly regulates IL6 gene transcription and downstream signaling activity. The GG genotype alters upstream ligand production, setting a higher baseline for potential signaling activity.
• Downstream expression: The CRP rs1205 polymorphism, located in the 3' untranslated region (3'UTR) of the CRP gene, directly modulates mRNA stability, altering the baseline production and downstream capacity of hs-CRP.
• Synergistic signaling: Together, these variants act hierarchically. The upstream IL6 promoter variant increases cytokine signaling "input," while the downstream CRP rs1205 variant dictates translational "output" responsiveness to that cytokine stimulus.

Clinical implications

• Amplified inflammatory response: Co-inheritance of these regulatory variants shifts the body's inflammatory set-point, causing hs-CRP to rise more readily when IL-6 signaling is active.
• Cardiovascular risk: In vulnerable cohorts, such as smokers, the combined presence of these risk genotypes is associated with significantly elevated inflammatory markers, worse endothelial function, and heightened cardiovascular risk compared to having either variant alone.

Bottom line

The IL6 rs1800795 GG and CRP rs1205 CT genotypes hierarchically amplify the IL-6-to-CRP axis, causing hs-CRP to rise more readily during active inflammatory states and potentially increasing susceptibility to cardiovascular and endothelial dysfunction.